Home / Resources / Q3 2024 Gene, Cell, + RNA Therapy Landscape Report
Q3 2024 Gene, Cell, + RNA Therapy Landscape Report

In Q3 2024, 51% of newly initiated gene therapy trials were for non-oncology indications, up from just 39% year-over-year.

Discover more by downloading the report.

''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
Related products
Getting the full drug RandD landscape
Pharmaprojects
世界的な医薬品研究開発の状況を追跡し、分析するための業界標準
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析
Analyst using Datamonitor Healthcare for a market assesment
Datamonitor Healthcare
推測なしでの製薬市場評価のための分析およびデータツール

Related resources

a person in a lab coat holding a plastic container with blue circles
APR 11, 2024
Report
商業化支援サービス

Gene, Cell, + RNA Therapy Landscape Report Q1 2024 Quarterly Data Report

The cell & gene therapy field has continued its momentum in Q1 2024 with several notable approvals and strong growth in all stages of clinical development.

Clinical-resource-ISCT Report_resource-card-thumbnail
JUN 01, 2023
Report
Clinical

Cell and Gene Therapy Global Regulatory Report

The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.

Watch the Commercialization of Cell and Gene Therapy webinar.
JUN 13, 2024
Webinar
Citeline

Commercialization of Cell and Gene Therapy

This on-demand webinar, presented in collaboration with the Indian Pharmaceutical Alliance and featuring Citeline's Pooja Rana, offers an in-depth analysis of the commercial landscape for cell and gene therapies.

View all